Evidence map›Paper›PMID 25674739›Full record

ArticleMedicine2015

Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses.

Fatma Alibaz-Oner, Asl Karadeniz, Sema Ylmaz, Ayşe Balkarl, Gezmiş Kimyon, Ayten Yazc, Muhammet Çnar, Sedat Ylmaz, Fatih Yldz, Şule Yaşar Bilge and 18 more

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 154 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 1 institution in 1 country.

Fatma Alibaz-OnerFrom the Marmara University, School of Medicine, Department of Rheumatology Istanbul (FA-O, AK, HD); Selçuk University, School of Medicine, Department of Rheumatology Konya (SY); Pamukkale University, School of Medicine, Department of Rheumatology Denizli (AB, VÇ); Gaziantep University, School of Medicine, Department of Rheumatology Gaziantep (GK, BK, AMO); Kocaeli University, School of Medicine, Department of Rheumatology Kocaeli (AY, AÇ); Gulhane Military School of Medicine, Department of Rheumatology Ankara (MÇ, SY, SP); Çukurova University, School of Medicine, Department of Rheumatology Adana (FY, EE); Osmangazi University, School of Medicine, Department of Rheumatology Eskişehir (ŞYB, TK); Hacettepe University, School of Medicine, Department of Rheumatology Ankara (EB, UK, ÖK); Uludağ University, School of Medicine, Department of Rheumatology Bursa (BNC, YP); Ankara Numune Training and Research Hospital, Department of Rheumatology, Ankara (AO); Sütçü İmam University, School of Medicine, Department of Rheumatology, Kahramanmaraş (GYÇ); Bilim University, School of Medicine, Department of Rheumatology, Istanbul (YÇ); Hitit University Medical Faculty, Department of Rheumatology, Çorum (YK); and Ondokuz Mayıs University, School of Medicine, Department of Rheumatology, Samsun, Turkey (MS).
Asl Karadeniz
Sema Ylmaz
Ayşe Balkarl
Gezmiş Kimyon
Ayten Yazc
Muhammet Çnar
Sedat Ylmaz
Fatih Yldz
Şule Yaşar Bilge
Emre Bilgin
Belkis Nihan Coskun
Ahmet Omma
Gözde Yldrm Çetin
Yonca Çağatay
Yaşar Karaaslan
Mehmet Sayarloğlu
Yavuz Pehlivan
Umut Kalyoncu
Ömer Karadağ
Timuçin Kaşifoğlu
Eren Erken
Salih Pay
Ayşe Çefle
Bünyamin Ksack
Ahmet Mesut Onat
Veli Çobankara
Haner Direskeneli
Cukurova University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular involvement is one of the major causes of mortality and morbidity in Behçet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively.Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 ± 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired.VBD was observed in 27.7% (n = 260) of the patients during follow-up. In 57.3% of the VBD patients, vascular involvement was the presenting sign of the disease. After the first vascular event, ISs were given to 88.8% and AC treatment to 59.8% of the patients. Median duration of AC treatment was 13 months (1-204) and ISs, 22 months (1-204). Minor hemorrhage related to AC treatment was observed in 7 (4.7%) patients. A second vascular event developed in 32.9% (n = 86) of the patients. The vascular relapse rate was similar between patients taking only ISs and AC plus IS treatments after the first vascular event (29.1% vs 22.4%, P = 0.28) and was significantly higher in group taking only ACs than taking only ISs (91.6% vs 29.1%, P < 0.001). During follow-up, a third vascular event developed in 17 (n = 6.5%) patients. The relapse rate was also similar between the patients taking only ISs and AC plus IS treatments after second vascular event (25.3% vs 20.8%, P = 0.93). When multivariate analysis was performed, development of vascular relapse negatively correlated with only IS treatments.We did not find any additional positive effect of AC treatment used in combination with ISs in the course of vascular involvement in patients with BD. Severe complications related to AC treatment were also not detected. Our results suggest that short duration of IS treatments and compliance issues of treatment are the major problems in VBD associated with vascular relapses during follow-up.

Indexed as

AdultBehcet SyndromeFemaleFollow-Up StudiesHumansMaleRecurrenceRetrospective StudiesVasculitis

Identifiers

PMID25674739
PMCPMC4602744
OpenAlexW2022237635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.